 | Up a level |
Dreyling, Martin; Doorduijn, Jeanette; Giné, Eva; Jerkeman, Mats; Walewski, Jan; Hutchings, Martin; Mey, Ulrich; Riise, Jon; Trneny, Marek; Vergote, Vibeke; Shpilberg, Ofer; Gomes da Silva, Maria; Leppä, Sirpa; Jiang, Linmiao; Stilgenbauer, Stephan; Kerkhoff, Andrea; Jachimowicz, Ron D; Celli, Melania; Hess, Georg; Arcaini, Luca; ... (2024). Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. (In Press). The lancet Elsevier 10.1016/S0140-6736(24)00184-3
Stathis, Anastasios; Mey, Ulrich J M; Schär, Sämi; Hitz, Felicitas; Pott, Christiane; Mach, Nicolas; Krasniqi, Fatime; Novak, Urban; Schmidt, Christian; Hohloch, Karin; Kienle, Dirk Lars; Hess, Dagmar; Moccia, Alden A; Unterhalt, Michael; Eckhardt, Katrin; Hayoz, Stefanie; Forestieri, Gabriela; Rossi, Davide; Dirnhofer, Stefan; Ceriani, Luca; ... (2022). SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood advances, 6(13), pp. 3911-3920. American Society of Hematology 10.1182/bloodadvances.2021006520
